Latest Healthcare Research Reports

Tag: cancer profiling market size

Cancer Profiling Market Forecast Highlights Expansion From $16.67 Billion To $25.62 Billion Through 2030

Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.

Cancer Profiling Market Growth From $16.67 Billion In 2026 To $25.62 Billion By 2030 At A CAGR Of 11.3%

The field of cancer profiling has witnessed substantial expansion lately. Projected to increase from a valuation of $15 billion in 2025 to $16.67 billion by 2026, this growth reflects a compound annual growth rate of 11.1%. Factors contributing to the expansion observed during the earlier period include a rise in cancer occurrences, a broader establishment of molecular diagnostics facilities, earlier integration of genetic testing within cancer care, an increase in research endeavors focused on cancer profiling, and the greater accessibility of diagnostic technologies.

The market for cancer profiling is poised for substantial expansion in the upcoming years, projecting a reach of $25.62 billion by 2030, propelled by a compound annual growth rate (CAGR) of 11.3%. This anticipated growth is largely fueled by a rising embrace of precision medicine strategies, the broadening scope of companion diagnostics, widespread adoption of liquid biopsy methods, escalating investments in cancer diagnostics, and the increasing incorporation of profiling into standard clinical practices. Key developments shaping this period include a greater reliance on next-generation sequencing (NGS) for cancer profiling, increased utilization of extensive genomic panels, enhanced integration of artificial intelligence for data analysis, the proliferation of personalized oncology diagnostics, and a heightened emphasis on identifying molecular markers early in the disease process.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9912&type=smp

Cancer Profiling Market Expansion Drivers: What Is Shaping Future Growth?

The projected rise in cancer occurrences is anticipated to fuel the expansion of the cancer profiling market in the future. Cancer incidence, signifying the count of new cancer diagnoses within a defined demographic over a specific timeframe, is escalating due to factors such as increasing urbanization, an aging global population, evolving lifestyle patterns, and a combination of environmental and hereditary influences. Cancer profiling serves a crucial role in pinpointing unique molecular or genetic alterations within a tumor, including gene mutations or other anomalies in tumor DNA, thereby contributing significantly to the cancer treatment continuum. For example, data from July 2024, citing the Australian Institute of Health and Welfare, a governmental body in Australia, indicated that an estimated 165,000 individuals in Australia received a new cancer diagnosis in 2023, translating to more than 450 diagnoses daily, with males accounting for approximately 55% of these cases. Consequently, the escalating rate of cancer incidence is a primary catalyst for the growth trajectory of the cancer profiling market.

Cancer Profiling Market Segment Breakdown: Which Categories Generate The Most Revenue?

The cancer profiling market covered in this report is segmented –

1) By Technology: Immunoassays, PCR (Polymerized Chain Reaction), NGS (Next-Generation Sequencing), Microarrays, In-Situ Hybridization

2) By Biomarker Type: Genomic Biomarkers, Protein Biomarkers

3) By Cancer Type: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer, Other Cancers

4) By Application: Research Applications, Clinical Applications, Diagnostics, Prognostics, Other Applications

Subsegments:

1) By Immunoassays: Enzyme-Linked Immunosorbent Assay (ELISA), Western Blotting, Luminex xMAP Technology

2) By PCR (Polymerase Chain Reaction): Quantitative PCR (qPCR), Digital PCR (dPCR), Reverse Transcription PCR (RT-PCR)

3) By NGS (Next-Generation Sequencing): Whole Genome Sequencing (WGS), Whole Exome Sequencing (WES), Targeted Sequencing, RNA Sequencing (RNA-Seq)

4) By Microarrays: DNA Microarrays, RNA Microarrays, SNP Arrays

5) By In-Situ Hybridization: Fluorescence In-Situ Hybridization (FISH), Chromogenic In-Situ Hybridization (CISH)

Cancer Profiling Market Strategic Trends: What Is Defining The Next Phase Of Growth?

To gain a competitive edge within the cancer profiling sector, leading companies are prioritizing innovations like integrated whole-exome sequencing (WES) and whole-transcriptome sequencing (WTS) methodologies. These advanced assays are designed to deliver more thorough, tissue-efficient, and clinically relevant diagnostic insights for precision cancer treatment. By merging DNA (exome) and RNA (transcriptome) analysis into a singular process, these tests can identify both genetic alterations such as single nucleotide variants, insertions/deletions, and copy number variations, in addition to gene expression patterns or fusion events. This contrasts with older methods that either necessitated separate tests or were limited to examining only a select group of genes, thereby offering less comprehensive data. A notable development occurred in November 2024 when Caris Life Sciences, a US firm specializing in precision medicine, secured FDA clearance for MI Cancer Seek, an innovative next-generation sequencing in vitro diagnostic tool capable of performing WES and WTS concurrently. This particular assay leverages total nucleic acid extracted from formalin-fixed paraffin-embedded (FFPE) tumor samples to proficiently detect single nucleotide variants, insertions and deletions affecting 228 genes, microsatellite instability (MSI), tumor mutational burden (TMB), and copy number amplifications, specifically in breast cancer cases. The strategic advantage of consolidating both DNA and RNA profiling within a single examination lies in its capacity to conserve valuable tissue samples, provide actionable companion diagnostic (CDx) insights applicable to a diverse range of cancer types, and expedite the selection of therapeutic strategies by offering a unified genomic profile.

Cancer Profiling Market Key Players And Strategic Industry Positioning

Major companies operating in the cancer profiling market are Illumina Inc., Qiagen NV, NeoGenomics Inc., Sysmex Corporation, HTG Molecular Diagnostics Inc., Caris Life Sciences, NanoString Technologies Inc., Guardant Health Inc., Foundation Medicine Inc., Roche Diagnostics Corporation, F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Genscript Biotech Corporation, Tempus Labs Inc., Hologic Inc., Predictive Oncology Inc., Abbott Laboratories, Agilent Technologies Inc., PerkinElmer Inc., Siemens Healthineers, Genomic Health Inc., Natera Inc., ArcherDX Inc., Personal Genome Diagnostics Inc., Enzo Biochem Inc., Cancer Genetics Inc., OncoDNA SA, Ribomed Biotechnologies Inc., Biocartis Group NV, N-of-One Inc., Cynvenio Biosystems Inc., Inivata Ltd., Burning Rock Biotech Limited, PathAI Inc., GENEWIZ Inc., Genoptix Inc., OmniSeq Comprehensive, Resolution Bioscience, OncoCyte Corporation

Access The Complete Cancer Profiling Market Report:

https://www.thebusinessresearchcompany.com/report/cancer-profiling-global-market-report

Cancer Profiling Market Geographic Landscape: Which Region Dominates Industry Growth?

North Americawas the largest region in the cancer profiling market in 2025. The regions covered in the cancer profiling market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

June 19, 2026
Rising Cancer Incidence Fuels Growth In Cancer Profiling Market Continues To Impact The Growth Of The Cancer Profiling Market

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Growth In Market Value Is Anticipated For The Cancer Profiling Market Between 2026 And 2030?

The cancer stem cells market has experienced significant growth in recent years. This market is projected to expand from $3.24 billion in 2025 to $3.59 billion in 2026, showing a compound annual growth rate (CAGR) of 10.6%. Historically, this growth can be attributed to advancements in stem cell biology research, the identification of cancer stem cell populations, increased funding for oncology research, the expansion of preclinical cancer models, and rising academic-industry collaborations.

The cancer stem cells market size is projected to experience swift expansion over the coming years. This market is anticipated to reach a valuation of $5.31 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 10.3%. Factors contributing to this growth during the projection period include the rising need for long-lasting cancer treatments, increased funding for targeted oncology studies, broader implementation of individualized cancer therapy approaches, a heightened emphasis on preventing metastasis, and the greater incorporation of CSC research into clinical oncology practices. Key trends identified for the forecast timeframe encompass an intensified focus on developing treatments for therapy-resistant cancer cells, more extensive investigation into CSC-specific biological pathways, advancing the creation of CSC biomarkers, broader scope in translational and clinical CSC research, and improved utilization of CSC models within drug discovery processes.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9912&type=smp

Which Strategic Drivers Are Supporting The Cancer Profiling Market Development?

The increasing need for personalized medicine is anticipated to drive expansion in the cancer stem cells market in the foreseeable future. Personalized medicine involves therapeutic strategies crafted specifically for each patient’s genetic profile, tumor characteristics, and individual reactions to treatment, aiming for enhanced efficacy and reduced adverse effects. The growing appetite for personalized medicine is fueled by the accessibility of genomic sequencing technologies, which are progressively more cost-effective and extensively applied in cancer research and patient treatment. By customizing therapies to match the distinct molecular and genetic features of a patient’s tumor, personalized medicine specifically addresses cancer stem cells (CSCs). Initial analysis of tumors identifies mutations, signaling pathways, and surface markers particular to their CSC population, enabling medical professionals to choose treatments that block essential pathways. An example of this trend is that in February 2024, the Personalized Medicine Coalition, a US-based hospital and health care organization, reported that the Food and Drug Administration (FDA) sanctioned 16 novel personalized treatments for patients with rare diseases in 2023, an increase from six in 2022. Therefore, the increasing demand for real-time risk assessment and mitigation solutions is fostering the expansion of the cancer stem cells market.

Which Segment Groups Define The Cancer Profiling Market Landscape?

The cancer profiling market covered in this report is segmented –

1) By Technology: Immunoassays, PCR (Polymerized Chain Reaction), NGS (Next-Generation Sequencing), Microarrays, In-Situ Hybridization

2) By Biomarker Type: Genomic Biomarkers, Protein Biomarkers

3) By Cancer Type: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer, Other Cancers

4) By Application: Research Applications, Clinical Applications, Diagnostics, Prognostics, Other Applications

Subsegments:

1) By Immunoassays: Enzyme-Linked Immunosorbent Assay (ELISA), Western Blotting, Luminex xMAP Technology

2) By PCR (Polymerase Chain Reaction): Quantitative PCR (qPCR), Digital PCR (dPCR), Reverse Transcription PCR (RT-PCR)

3) By NGS (Next-Generation Sequencing): Whole Genome Sequencing (WGS), Whole Exome Sequencing (WES), Targeted Sequencing, RNA Sequencing (RNA-Seq)

4) By Microarrays: DNA Microarrays, RNA Microarrays, SNP Arrays

5) By In-Situ Hybridization: Fluorescence In-Situ Hybridization (FISH), Chromogenic In-Situ Hybridization (CISH)

What Trends Are Influencing The Cancer Profiling Market?

Companies operating within the cancer stem cells market are increasingly concentrating on technological advancements, such as pre-analytical immunomagnetic sorting systems, to improve cell enrichment for better diagnostic precision. These pre-analytical immunomagnetic sorting systems are sophisticated instruments that utilize magnetic particles coated with antibodies to isolate specific cancer stem cell populations from complex biological samples, thereby enhancing sensitivity and reproducibility in subsequent assays. For instance, in March 2024, STEMCELL Technologies, a Canada-based biotechnology company, introduced the EasySep Human Bone Marrow CD138 Positive Selection Kit. This kit represents the first hematopoietic cell enrichment product to obtain FDA de novo classification as a Class II in vitro diagnostic device. It functions by enriching CD138+ plasma cells from bone marrow samples to enhance the identification of abnormalities linked to multiple myeloma. The product guarantees elevated sensitivity, reproducibility, and diagnostic accuracy, ultimately leading to improved patient outcomes in multiple myeloma care. The fundamental aim of this product is to fortify the pre-analytical phase of cancer diagnostics by providing highly pure cell populations, which facilitates more dependable downstream testing.

Which Companies Are Engaged In The Cancer Profiling Market Environment?

Major companies operating in the cancer profiling market are Illumina Inc., Qiagen NV, NeoGenomics Inc., Sysmex Corporation, HTG Molecular Diagnostics Inc., Caris Life Sciences, NanoString Technologies Inc., Guardant Health Inc., Foundation Medicine Inc., Roche Diagnostics Corporation, F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Genscript Biotech Corporation, Tempus Labs Inc., Hologic Inc., Predictive Oncology Inc., Abbott Laboratories, Agilent Technologies Inc., PerkinElmer Inc., Siemens Healthineers, Genomic Health Inc., Natera Inc., ArcherDX Inc., Personal Genome Diagnostics Inc., Enzo Biochem Inc., Cancer Genetics Inc., OncoDNA SA, Ribomed Biotechnologies Inc., Biocartis Group NV, N-of-One Inc., Cynvenio Biosystems Inc., Inivata Ltd., Burning Rock Biotech Limited, PathAI Inc., GENEWIZ Inc., Genoptix Inc., OmniSeq Comprehensive, Resolution Bioscience, OncoCyte Corporation

Access The Complete Cancer Profiling Market Report:

https://www.thebusinessresearchcompany.com/report/cancer-profiling-global-market-report

Which Region Holds The Largest Share In The Cancer Profiling Market?

North America was the largest region in the cancer profiling market in 2025. The regions covered in the cancer profiling market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Cancer Profiling Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=9912&type=smp

Browse Through More Reports Similar to the Global Cancer Profiling Market 2026, By The Business Research Company

Hydraulics Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/hydraulics-global-market-report

Smart Elevators Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/smart-elevators-global-market-report

Hydraulic Pumps Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/hydraulic-pumps-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

May 26, 2026
Global cancer profiling market to reach $25.62B by 2030 at 11.3% CAGR

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Will The Market Value Of The Cancer Profiling Market Progress Between 2026 And 2030?

The cancer profiling market has experienced substantial growth in recent years. It is anticipated to expand from $15 billion in 2025 to $16.67 billion in 2026, achieving a compound annual growth rate (CAGR) of 11.1%. The increase observed in previous periods is attributable to factors like a surge in cancer incidence rates, the expansion of molecular diagnostics laboratories, the early integration of genomic testing in oncology, an increase in research-based cancer profiling, and the growing availability of diagnostic platforms.

The cancer profiling market is anticipated to experience significant expansion in the coming years. This market is projected to reach $25.62 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 11.3%. This expansion during the forecast period can be attributed to several factors, including a heightened demand for precision medicine approaches, the proliferation of companion diagnostics, the broader application of liquid biopsy technologies, increased investments in oncology diagnostics, and the greater incorporation of profiling into standard clinical workflows. Key trends anticipated during this period encompass the wider adoption of ngs-based cancer profiling, an increase in the utilization of comprehensive genomic panels, the growing integration of ai for data interpretation, the expansion of personalized oncology diagnostics, and an intensified focus on early molecular detection.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/cancer-profiling-global-market-report

Which Primary Drivers Are Impacting The Cancer Profiling Market Growth?

The projected expansion of the cancer profiling market is anticipated to be fueled by the rising occurrence of cancer. Cancer incidence quantifies the new diagnoses within a particular demographic over a defined timeframe. This escalation in cancer cases stems from factors such as increased urbanization, an expanding elderly population, evolving lifestyle choices, and various environmental and genetic influences. Cancer profiling facilitates the detection of distinct molecular or genetic alterations within a tumor, including gene mutations or other modifications in tumor DNA, thereby proving beneficial throughout the cancer treatment process. For example, data from July 2024, provided by the Australian Institute of Health and Welfare, an Australian governmental body, revealed that in 2023, approximately 165,000 Australians received a new cancer diagnosis, translating to more than 450 cases daily, with males accounting for roughly 55% of these new diagnoses. Consequently, the growing prevalence of cancer is a key impetus behind the expansion of the cancer profiling market.

What Are The Different Segment Types In The Cancer Profiling Market Segment Breakdown?

The cancer profiling market covered in this report is segmented –

1) By Technology: Immunoassays, PCR (Polymerized Chain Reaction), NGS (Next-Generation Sequencing), Microarrays, In-Situ Hybridization

2) By Biomarker Type: Genomic Biomarkers, Protein Biomarkers

3) By Cancer Type: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer, Other Cancers

4) By Application: Research Applications, Clinical Applications, Diagnostics, Prognostics, Other Applications

Subsegments:

1) By Immunoassays: Enzyme-Linked Immunosorbent Assay (ELISA), Western Blotting, Luminex xMAP Technology

2) By PCR (Polymerase Chain Reaction): Quantitative PCR (qPCR), Digital PCR (dPCR), Reverse Transcription PCR (RT-PCR)

3) By NGS (Next-Generation Sequencing): Whole Genome Sequencing (WGS), Whole Exome Sequencing (WES), Targeted Sequencing, RNA Sequencing (RNA-Seq)

4) By Microarrays: DNA Microarrays, RNA Microarrays, SNP Arrays

5) By In-Situ Hybridization: Fluorescence In-Situ Hybridization (FISH), Chromogenic In-Situ Hybridization (CISH)

Which Trends Are Shaping Growth In The Cancer Profiling Market?

Major companies operating in the cancer profiling market are prioritizing technological advancements, such as simultaneous whole-exome sequencing (WES) and whole-transcriptome sequencing (WTS) assays, to deliver more comprehensive, tissue-sparing, and clinically actionable molecular diagnostics for precision oncology. These assays integrate DNA (exome) and RNA (transcriptome) analysis within a single workflow, enabling the detection of genomic variants (like SNVs, indels, and copy-number alterations) alongside gene expression or fusion events, which differs from traditional NGS tests that require separate assays or limited gene panels. For instance, in November 2024, Caris Life Sciences, a US-based precision medicine company, secured FDA approval for MI Cancer Seek, an NGS in vitro diagnostic that performs WES and WTS concurrently. This assay utilizes total nucleic acid (TNA) sourced from FFPE tumor tissue to detect single-nucleotide variants, insertions or deletions across 228 genes, microsatellite instability (MSI), tumor mutational burden (TMB), and copy-number amplifications specifically in breast cancer. By consolidating DNA and RNA profiling into one test, it conserves tissue, provides clinically actionable companion diagnostic (CDx) indications across multiple tumor types, and expedites therapy selection through a unified genomic blueprint.

Who Are The Well-Known Companies In The Cancer Profiling Market?

Major companies operating in the cancer profiling market are Illumina Inc., Qiagen NV, NeoGenomics Inc., Sysmex Corporation, HTG Molecular Diagnostics Inc., Caris Life Sciences, NanoString Technologies Inc., Guardant Health Inc., Foundation Medicine Inc., Roche Diagnostics Corporation, F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Genscript Biotech Corporation, Tempus Labs Inc., Hologic Inc., Predictive Oncology Inc., Abbott Laboratories, Agilent Technologies Inc., PerkinElmer Inc., Siemens Healthineers, Genomic Health Inc., Natera Inc., ArcherDX Inc., Personal Genome Diagnostics Inc., Enzo Biochem Inc., Cancer Genetics Inc., OncoDNA SA, Ribomed Biotechnologies Inc., Biocartis Group NV, N-of-One Inc., Cynvenio Biosystems Inc., Inivata Ltd., Burning Rock Biotech Limited, PathAI Inc., GENEWIZ Inc., Genoptix Inc., OmniSeq Comprehensive, Resolution Bioscience, OncoCyte Corporation

Get The Full Cancer Profiling Market Report:

https://www.thebusinessresearchcompany.com/report/cancer-profiling-global-market-report

Which Region Is The Largest In The Cancer Profiling Market?

North America was the largest region in the cancer profiling market in 2025. The regions covered in the cancer profiling market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Cancer Profiling Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/cancer-profiling-global-market-report

Browse Through More Reports Similar to the Global Cancer Profiling Market 2026, By The Business Research Company

Cancer Diagnostics Market Report 2026

https://www.thebusinessresearchcompany.com/report/cancer-diagnostics-global-market-report

Cancer Tumor Profiling Market Report 2026

https://www.thebusinessresearchcompany.com/report/cancer-tumor-profiling-global-market-report

Cancer Biomarker Market Report 2026

https://www.thebusinessresearchcompany.com/report/cancer-biomarker-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

April 20, 2026
Global Cancer Profiling Market Expected to Reach $25.62 Billion by 2030 with 11.3% CAGR

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Large Is The Cancer Profiling Market Projected To Become By 2030 Based On Its 2026 Valuation?

The cancer profiling market size has experienced rapid growth in recent years. It is anticipated to expand from $15 billion in 2025 to $16.67 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 11.1%. The increase observed in the historic period stems from escalating cancer incidence rates, the proliferation of molecular diagnostics laboratories, the early embrace of genomic testing in oncology, an uptick in research-based cancer profiling, and the growing accessibility of diagnostic platforms.

The cancer profiling market size is anticipated to undergo swift expansion in the next few years. This market is projected to reach $25.62 billion by 2030, expanding at a compound annual growth rate (CAGR) of 11.3%. The expansion during the forecast period is primarily driven by several factors, including the escalating demand for precision medicine approaches, the broader application of companion diagnostics, the rising utilization of liquid biopsy technologies, increasing investments in oncology diagnostics, and the growing incorporation of profiling into routine clinical workflows. Key trends anticipated in the forecast period involve the increasing adoption of NGS-based cancer profiling, the expanding use of comprehensive genomic panels, the growing integration of AI in data interpretation, the wider availability of personalized oncology diagnostics, and a heightened emphasis on early molecular detection.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9912&type=smp

Which Market Drivers Are Supporting The Expansion Of The Cancer Profiling Market?

The expanding occurrence of cancer is projected to boost the growth of the cancer profiling market in the foreseeable future. Cancer incidence refers to the count of new cancer cases identified within a particular population over a specified duration. The heightened incidence of cancer is attributable to factors such as urbanization, an expanding elderly demographic, evolving lifestyle choices, alongside environmental and genetic influences. Cancer profiling serves to identify specific molecular or genetic alterations in a tumor, such as gene mutations or other changes in tumor DNA, which is advantageous throughout the cancer treatment cycle. For example, in July 2024, the Australian Institute of Health and Welfare, an Australia-based government agency, stated that an estimated 165,000 Australians received a new cancer diagnosis in 2023, equating to over 450 cases daily, with males making up approximately 55% of these diagnoses. Hence, the rising incidence of cancer is propelling the growth of the cancer profiling market.

What Segment Groups Are Identified Within The Cancer Profiling Market?

The cancer profiling market covered in this report is segmented –

1) By Technology: Immunoassays, PCR (Polymerized Chain Reaction), NGS (Next-Generation Sequencing), Microarrays, In-Situ Hybridization

2) By Biomarker Type: Genomic Biomarkers, Protein Biomarkers

3) By Cancer Type: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer, Other Cancers

4) By Application: Research Applications, Clinical Applications, Diagnostics, Prognostics, Other Applications

Subsegments:

1) By Immunoassays: Enzyme-Linked Immunosorbent Assay (ELISA), Western Blotting, Luminex xMAP Technology

2) By PCR (Polymerase Chain Reaction): Quantitative PCR (qPCR), Digital PCR (dPCR), Reverse Transcription PCR (RT-PCR)

3) By NGS (Next-Generation Sequencing): Whole Genome Sequencing (WGS), Whole Exome Sequencing (WES), Targeted Sequencing, RNA Sequencing (RNA-Seq)

4) By Microarrays: DNA Microarrays, RNA Microarrays, SNP Arrays

5) By In-Situ Hybridization: Fluorescence In-Situ Hybridization (FISH), Chromogenic In-Situ Hybridization (CISH)

What Trends Are Advancing Progress In The Cancer Profiling Market?

Leading companies within the cancer profiling market are increasingly concentrating on technological advancements, such as simultaneous whole-exome sequencing (WES) and whole-transcriptome sequencing (WTS) assays. These innovations aim to deliver more exhaustive, tissue-conservative, and clinically relevant molecular diagnostics essential for precision oncology. These assays integrate DNA (exome) and RNA (transcriptome) analysis into a single workflow, allowing for the detection of genomic variants including SNVs, indels, and copy-number alterations, alongside gene expression or fusion events, distinguishing them from traditional NGS tests that typically require separate assays or limited gene panels. For example, in November 2024, Caris Life Sciences, a US-based precision medicine company, received FDA approval for MI Cancer Seek. This NGS in vitro diagnostic performs WES and WTS concurrently. The assay uses total nucleic acid (TNA) from FFPE tumor tissue to detect single-nucleotide variants, insertions or deletions across 228 genes, microsatellite instability (MSI), tumor mutational burden (TMB), and copy-number amplifications in breast cancer. Through the integration of DNA and RNA profiling into one test, it preserves tissue, offers clinically actionable companion diagnostic (CDx) indications across multiple tumor types, and speeds up therapy selection by providing a unified genomic blueprint.

Which Companies Hold Significant Positions In The Cancer Profiling Market?

Major companies operating in the cancer profiling market are Illumina Inc., Qiagen NV, NeoGenomics Inc., Sysmex Corporation, HTG Molecular Diagnostics Inc., Caris Life Sciences, NanoString Technologies Inc., Guardant Health Inc., Foundation Medicine Inc., Roche Diagnostics Corporation, F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Genscript Biotech Corporation, Tempus Labs Inc., Hologic Inc., Predictive Oncology Inc., Abbott Laboratories, Agilent Technologies Inc., PerkinElmer Inc., Siemens Healthineers, Genomic Health Inc., Natera Inc., ArcherDX Inc., Personal Genome Diagnostics Inc., Enzo Biochem Inc., Cancer Genetics Inc., OncoDNA SA, Ribomed Biotechnologies Inc., Biocartis Group NV, N-of-One Inc., Cynvenio Biosystems Inc., Inivata Ltd., Burning Rock Biotech Limited, PathAI Inc., GENEWIZ Inc., Genoptix Inc., OmniSeq Comprehensive, Resolution Bioscience, OncoCyte Corporation

Read the full cancer profiling market report here:

https://www.thebusinessresearchcompany.com/report/cancer-profiling-global-market-report

How Is The Cancer Profiling Market Distributed Across Key Geographic Regions?

North America was the largest region in the cancer profiling market in 2025. The regions covered in the cancer profiling market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Cancer Profiling Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=9912&type=smp

Browse Through More Reports Similar to the Global Cancer Profiling Market 2026, By The Business Research Company

Hydraulics Global Market Report

https://www.thebusinessresearchcompany.com/report/hydraulics-global-market-report

Smart Elevators Global Market Report

https://www.thebusinessresearchcompany.com/report/smart-elevators-global-market-report

Hydraulic Pumps Global Market Report

https://www.thebusinessresearchcompany.com/report/hydraulic-pumps-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

March 30, 2026
Cancer Profiling Market Future Outlook 2026: Key Drivers and Growth Potential

Uncover key drivers, emerging technologies, and competitive movements shaping the cancer profiling market from 2026–2035 with trusted insights from The Business Research Company

What long-term size projections exist for the Cancer Profiling Market covering 2026–2035?

The cancer profiling market has experienced swift expansion in recent years. Its value is projected to rise from $15 billion in 2025 to $16.67 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 11.1%. This historical growth can be attributed to factors such as increasing cancer incidence rates, the expansion of molecular diagnostics laboratories, the early adoption of genomic testing in oncology, the growth in research-based cancer profiling, and the rising availability of diagnostic platforms.

The cancer profiling market is poised for significant expansion over the coming years. By 2030, this market is projected to reach $25.62 billion, exhibiting a compound annual growth rate (CAGR) of 11.3%. This anticipated growth is driven by several factors, including the escalating demand for precision medicine approaches, the broadening scope of companion diagnostics, the increasing adoption of liquid biopsy technologies, greater investments in oncology diagnostics, and the enhanced incorporation of profiling into standard clinical procedures. Key trends expected during this period involve the rising uptake of ngs-based cancer profiling, the expanding utilization of comprehensive genomic panels, the increasing incorporation of AI in data interpretation, the widening availability of personalized oncology diagnostics, and a heightened emphasis on early molecular detection.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9912&type=smp

Which Drivers Are Impacting The Competitive Landscape Of The Cancer Profiling Market?

A rise in cancer cases is expected to propel the growth of the cancer profiling market in the coming years. Cancer incidence refers to the number of new cancer diagnoses observed in a specific population over a given timeframe. This elevated occurrence of cancer is caused by urbanization, an expanding aging population, evolving lifestyles, and environmental and genetic factors. Cancer profiling assists in pinpointing distinct molecular or genetic changes within a tumor, such as gene mutations or other alterations in tumor DNA, which proves beneficial in the cancer treatment cycle. For instance, in July 2024, data from the Australian Institute of Health and Welfare, an Australia-based government agency, indicated that in 2023, an estimated 165,000 Australians received a new cancer diagnosis, which equates to over 450 cases each day, and males accounted for about 55% of these diagnoses. Therefore, the increasing incidence of cancer is driving the growth of the cancer profiling market.

What Segments Are Identified Within The Structure Of The Cancer Profiling Market?

The cancer profiling market covered in this report is segmented –

1) By Technology: Immunoassays, PCR (Polymerized Chain Reaction), NGS (Next-Generation Sequencing), Microarrays, In-Situ Hybridization

2) By Biomarker Type: Genomic Biomarkers, Protein Biomarkers

3) By Cancer Type: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer, Other Cancers

4) By Application: Research Applications, Clinical Applications, Diagnostics, Prognostics, Other Applications

Subsegments:

1) By Immunoassays: Enzyme-Linked Immunosorbent Assay (ELISA), Western Blotting, Luminex xMAP Technology

2) By PCR (Polymerase Chain Reaction): Quantitative PCR (qPCR), Digital PCR (dPCR), Reverse Transcription PCR (RT-PCR)

3) By NGS (Next-Generation Sequencing): Whole Genome Sequencing (WGS), Whole Exome Sequencing (WES), Targeted Sequencing, RNA Sequencing (RNA-Seq)

4) By Microarrays: DNA Microarrays, RNA Microarrays, SNP Arrays

5) By In-Situ Hybridization: Fluorescence In-Situ Hybridization (FISH), Chromogenic In-Situ Hybridization (CISH)

Which Market Trends Are Opening Growth Opportunities In The Cancer Profiling Market?

Leading companies in the cancer profiling market are concentrating on technological breakthroughs, such as concurrent whole-exome sequencing (WES) and whole-transcriptome sequencing (WTS) assays. These innovations aim to offer more exhaustive, tissue-saving, and clinically applicable molecular diagnostics crucial for precision oncology. These assays integrate DNA (exome) and RNA (transcriptome) analysis within a singular workflow, allowing for the detection of genomic variants (including SNVs, indels, and copy-number alterations) alongside gene expression or fusion events, a contrast to conventional NGS tests that demand separate assays or use restricted gene panels. For example, in November 2024, Caris Life Sciences, a US-based precision medicine firm, obtained FDA approval for MI Cancer Seek. This NGS in vitro diagnostic is designed to perform WES and WTS simultaneously. The assay employs total nucleic acid (TNA) from FFPE tumor tissue to identify single-nucleotide variants, insertions or deletions across 228 genes, microsatellite instability (MSI), tumor mutational burden (TMB), and copy-number amplifications, particularly in breast cancer. By consolidating DNA and RNA profiling into one test, it preserves tissue, yields clinically actionable companion diagnostic (CDx) indications for various tumor types, and expedites therapy selection by providing a unified genomic blueprint.

Which Major Industry Participants Are Leading The Cancer Profiling Market Growth?

Major companies operating in the cancer profiling market are Illumina Inc., Qiagen NV, NeoGenomics Inc., Sysmex Corporation, HTG Molecular Diagnostics Inc., Caris Life Sciences, NanoString Technologies Inc., Guardant Health Inc., Foundation Medicine Inc., Roche Diagnostics Corporation, F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Genscript Biotech Corporation, Tempus Labs Inc., Hologic Inc., Predictive Oncology Inc., Abbott Laboratories, Agilent Technologies Inc., PerkinElmer Inc., Siemens Healthineers, Genomic Health Inc., Natera Inc., ArcherDX Inc., Personal Genome Diagnostics Inc., Enzo Biochem Inc., Cancer Genetics Inc., OncoDNA SA, Ribomed Biotechnologies Inc., Biocartis Group NV, N-of-One Inc., Cynvenio Biosystems Inc., Inivata Ltd., Burning Rock Biotech Limited, PathAI Inc., GENEWIZ Inc., Genoptix Inc., OmniSeq Comprehensive, Resolution Bioscience, OncoCyte Corporation

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/cancer-profiling-global-market-report

Which Region Is Expected To Experience The Fastest Growth In The Cancer Profiling Market?

North America was the largest region in the cancer profiling market in 2025. The regions covered in the cancer profiling market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Cancer Profiling Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=9912&type=smp

Browse Through More Reports Similar to the Global Cancer Profiling Market 2026, By The Business Research Company

Cancer Diagnostics Market Report 2026

https://www.thebusinessresearchcompany.com/report/cancer-diagnostics-global-market-report

Cancer Tumor Profiling Market Report 2026

https://www.thebusinessresearchcompany.com/report/cancer-tumor-profiling-global-market-report

Cancer Biomarker Market Report 2026

https://www.thebusinessresearchcompany.com/report/cancer-biomarker-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

February 20, 2026
Global Cancer Profiling Market Revenue and CAGR Forecast Analysis 2025–2029

Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

What Are The Future Growth Projections For The Cancer Profiling Market Size?

In recent years, the market size for cancer profiling has seen a significant expansion. It is projected to rise from $13.48 billion in 2024 to about $15 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 11.3%. The remarkable growth experienced during the historical period can be credited to the rising incidences of cancer, an increase in precision medicine methodologies, the clinical acceptance of biomarkers, the advancement of drugs and targeted treatments, heightened awareness, and patient advocacy.

The market size of cancer profiling is anticipated to witness a swift expansion in the coming years. It is projected to hit a benchmark of $22.97 billion in 2029, with a compound annual growth rate (CAGR) of 11.2%. The projected growth during the forecast period is attributed to factors like the incorporation of artificial intelligence, global research partnerships, the broadening scope of liquid biopsy applications, regulatory backing for precision medicine, and increased focus on early detection. Key trends expected during the forecast period encompass dominance of liquid biopsy, wide-ranging genomic profiling, the emergence of immunoprofiling, partnership in data sharing networks, and single-cell sequencing.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9912&type=smp

Which Demand Drivers Are Strengthening The Cancer Profiling Market?

The mounting occurrence of cancer is set to boost the expansion of the cancer profiling market in the future. Cancer incidence is the term used to denote the count of new cancer cases in a particular population over a certain duration. The ascending rate of cancer can be attributed to variables such as urbanization, an aging populace, lifestyle changes, and environmental and genetic contributors. Cancer profiling serves to detect distinctive molecular or genetic changes in a tumor – like gene mutations or other alterations in tumor DNA – which can be invaluable in the course of cancer treatment. For instance, the American Cancer Society, a volunteer organization based in the US, projected that in 2022 there would be about 1.9 million new diagnoses of cancer and roughly 609,360 cancer-related deaths in the United States. Thus, the escalating occurrence of cancer is acting as a growth catalyst for the cancer profiling market.

What Segmentation Insights Are Provided In The Cancer Profiling Market Research?

The cancer profilingmarket covered in this report is segmented –

1) By Technology: Immunoassays; PCR (Polymerized Chain Reaction); NGS (Next-Generation Sequencing); Microarrays; In-Situ Hybridization

2) By Biomarker Type: Genomic Biomarkers; Protein Biomarkers

3) By Cancer Type: Breast Cancer; Lung Cancer; Colorectal Cancer; Prostate Cancer; Melanoma Cancer; Other Cancers

4) By Application: Research Applications; Clinical Applications; Screening; Diagnostics; Prognostics; Other Applications

Subsegments:

1) By Immunoassays: Enzyme-Linked Immunosorbent Assay (ELISA); Western Blotting; Luminex xMAP Technology; Radioimmunoassays

2) By PCR (Polymerase Chain Reaction): Quantitative PCR (qPCR); Digital PCR (dPCR); Reverse Transcription PCR (RT-PCR)

3) By NGS (Next-Generation Sequencing): Whole Genome Sequencing (WGS); Whole Exome Sequencing (WES); Targeted Sequencing; RNA Sequencing (RNA-Seq)

4) By Microarrays: DNA Microarrays; RNA Microarrays; SNP Arrays

5) By In-Situ Hybridization: Fluorescence In-Situ Hybridization (FISH); Chromogenic In-Situ Hybridization (CISH)

Which Trends Are Likely To Redefine Growth Paths In The Cancer Profiling Market?

Prominent players in the cancer profiling market are prioritizing the development of innovative techniques, like broad coverage. This approach assesses 517 cancer-significant genes within approximately 30 different solid tumor categories. Broad coverage involves an extensive examination of various genetic mutations, biomarkers, or molecular targets. For example, in March 2022, the US biotech firm, Illumina, Inc., introduced the TruSight Oncology Comprehensive (TSO) test, ushering in a new era in cancer diagnostics. This new in vitro diagnostic test in Europe identifies cancer mutations to steer patients towards specialized therapies. It investigates 517 genes embedded in nearly 30 solid tumor classes, studying both DNA and RNA. It boasts a four- to five-day delivery timeframe for faster results and meets the CE mark for European quality standards, thereby minimizing the requirement for many gene assays on distinct tissue specimens.

Which Firms Are Driving Innovation Within The Cancer Profiling Market?

Major companies operating in the cancer profiling market include Illumina Inc., Qiagen NV, NeoGenomics Inc., Sysmex Corporation, HTG Molecular Diagnostics Inc., Caris Life Sciences, NanoString Technologies Inc., Guardant Health Inc., Foundation Medicine Inc., Roche Diagnostics Corporation, F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Genscript Biotech Corporation, Tempus Labs Inc., Hologic Inc., Predictive Oncology Inc., Abbott Laboratories, Agilent Technologies Inc., PerkinElmer Inc., Siemens Healthineers, Genomic Health Inc., Natera Inc., ArcherDX Inc., Personal Genome Diagnostics Inc., Enzo Biochem Inc., Cancer Genetics Inc., OncoDNA SA, Ribomed Biotechnologies Inc., Biocartis Group NV, N-of-One Inc., Cynvenio Biosystems Inc., Inivata Ltd., Burning Rock Biotech Limited, PathAI Inc., GENEWIZ Inc., Genoptix Inc., Oncomine Dx Target Test, OmniSeq Comprehensive, Resolution Bioscience, OncoCyte Corporation

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/cancer-profiling-global-market-report

Which Regional Markets Are Emerging As Key Hubs For The Cancer Profiling Market?

North America was the largest region in the cancer profiling market in 2024. The regions covered in the cancer profiling market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=9912&type=smp

Browse Through More Reports Similar to the Global Cancer Profiling Market 2025, By The Business Research Company

Pain Management Devices And Therapies Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/pain-management-devices-and-therapies-global-market-report

Metabolomics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/metabolomics-global-market-report

Isothermal Nucleic Acid Amplification Technology Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/isothermal-nucleic-acid-amplification-technology-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

November 28, 2025
Cancer Profiling Industry Forecast to Hit $22.97 Billion by 2029 With a Strong 11.2% CAGR

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

#What Are The Current (2025) And Forecast (2029) Sizes Of The Cancer Profiling Market?

The cancer profiling market has experienced rapid expansion in recent years. Its value is expected to rise from $13.48 billion in 2024 to $15 billion in 2025, achieving a compound annual growth rate (CAGR) of 11.3%. The historical drivers for this growth include increasing cancer incidence rates, the development of precision medicine approaches, the clinical integration of biomarkers, progress in drug development and targeted therapies, heightened awareness, and patient advocacy efforts.

The cancer profiling market is projected to experience swift expansion over the coming years, with its size anticipated to reach “$22.97 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 11.2%. Factors contributing to this growth during the forecast period include the integration of artificial intelligence, global collaborations in research, the expanding applications of liquid biopsy, regulatory support for precision medicine, and a heightened focus on early detection. Key trends identified for the forecast period encompass the dominance of liquid biopsy, comprehensive genomic profiling, the emergence of immunoprofiling, collaborative data sharing networks, and single-cell sequencing.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9912&type=smp

What Are The Key Drivers Of Growth In The Cancer Profiling Market?

The rising occurrence of cancer is anticipated to stimulate the expansion of the cancer profiling market moving forward. Cancer incidence refers to the count of newly diagnosed cancer cases within a specific population during a defined period. This increase in cancer cases is attributed to urbanization, an expanding aging demographic, evolving lifestyle habits, as well as environmental and genetic factors. Cancer profiling assists in identifying particular molecular or genetic changes in a tumor, such as gene mutations or other alterations in tumor DNA, which is valuable in the cancer treatment pathway. For example, in 2022, the American Cancer Society, a US-based voluntary organization, estimated that the United States would see approximately 1.9 million new cancer cases diagnosed and 609,360 cancer deaths. Therefore, the escalating incidence of cancer is a primary driver for the growth of the cancer profiling market.

What Are The Major Segment Types Covered In The Cancer Profiling Market?

The cancer profilingmarket covered in this report is segmented –

1) By Technology: Immunoassays; PCR (Polymerized Chain Reaction); NGS (Next-Generation Sequencing); Microarrays; In-Situ Hybridization

2) By Biomarker Type: Genomic Biomarkers; Protein Biomarkers

3) By Cancer Type: Breast Cancer; Lung Cancer; Colorectal Cancer; Prostate Cancer; Melanoma Cancer; Other Cancers

4) By Application: Research Applications; Clinical Applications; Screening; Diagnostics; Prognostics; Other Applications

Subsegments:

1) By Immunoassays: Enzyme-Linked Immunosorbent Assay (ELISA); Western Blotting; Luminex xMAP Technology; Radioimmunoassays

2) By PCR (Polymerase Chain Reaction): Quantitative PCR (qPCR); Digital PCR (dPCR); Reverse Transcription PCR (RT-PCR)

3) By NGS (Next-Generation Sequencing): Whole Genome Sequencing (WGS); Whole Exome Sequencing (WES); Targeted Sequencing; RNA Sequencing (RNA-Seq)

4) By Microarrays: DNA Microarrays; RNA Microarrays; SNP Arrays

5) By In-Situ Hybridization: Fluorescence In-Situ Hybridization (FISH); Chromogenic In-Situ Hybridization (CISH)

How Are Trends Influencing The Cancer Profiling Market?

Leading companies within the cancer profiling market are focused on developing innovations like broad coverage. Broad coverage entails the comprehensive analysis of a wide spectrum of genetic mutations, biomarkers, or molecular targets. For example, a test evaluates 517 cancer-relevant genes across nearly 30 solid tumor types. In March 2022, Illumina, Inc., a US-based biotechnology company, introduced the TruSight Oncology Comprehensive (TSO) test, which represented a significant advancement in cancer diagnostics. A new in vitro diagnostic test in Europe profiles cancer mutations to guide patients toward targeted therapies. This test spans 517 genes across nearly 30 solid tumor types, analyzing both DNA and RNA. With a rapid four- to five-day turnaround, it delivers faster results and is CE-marked for European quality standards, reducing the need for multiple gene assays on different tissue samples.

Which Leading Companies Dominate The Cancer Profiling Market Share?

Major companies operating in the cancer profiling market include Illumina Inc., Qiagen NV, NeoGenomics Inc., Sysmex Corporation, HTG Molecular Diagnostics Inc., Caris Life Sciences, NanoString Technologies Inc., Guardant Health Inc., Foundation Medicine Inc., Roche Diagnostics Corporation, F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Genscript Biotech Corporation, Tempus Labs Inc., Hologic Inc., Predictive Oncology Inc., Abbott Laboratories, Agilent Technologies Inc., PerkinElmer Inc., Siemens Healthineers, Genomic Health Inc., Natera Inc., ArcherDX Inc., Personal Genome Diagnostics Inc., Enzo Biochem Inc., Cancer Genetics Inc., OncoDNA SA, Ribomed Biotechnologies Inc., Biocartis Group NV, N-of-One Inc., Cynvenio Biosystems Inc., Inivata Ltd., Burning Rock Biotech Limited, PathAI Inc., GENEWIZ Inc., Genoptix Inc., Oncomine Dx Target Test, OmniSeq Comprehensive, Resolution Bioscience, OncoCyte Corporation

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/cancer-profiling-global-market-report

Which Geographies Are Emerging As Strong Markets For The Cancer Profiling Industry?

North America was the largest region in the cancer profiling market in 2024. The regions covered in the cancer profiling market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request A Customized Version Of The Cancer Profiling Market Report:

https://www.thebusinessresearchcompany.com/customise?id=9912&type=smp

Browse Through More Reports Similar to the Global Cancer Profiling Market 2025, By The Business Research Company

Pain Management Devices And Therapies Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/pain-management-devices-and-therapies-global-market-report

Metabolomics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/metabolomics-global-market-report

Isothermal Nucleic Acid Amplification Technology Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/isothermal-nucleic-acid-amplification-technology-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

November 24, 2025
Cancer ProfilingMarket Overview 2025–2034: CAGR Trends, Long-Term Growth Paths, and Business Implications

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

#How Fast Is The Cancer Profiling Market Expected to Grow Between 2025 And 2029?#_x000D_

Over the past years, the market size for cancer profiling has witnessed quick expansion. The market value, which stood at $13.48 billion in 2024, is predicted to increase to $15 billion in 2025, registering a compound annual growth rate (CAGR) of 11.3%. The substantial growth in the past can be credited to factors such as escalating rates of cancer cases, growth in precision medicine methods, the clinical utilization of biomarkers, drug development and targeted therapies, increased awareness, and patient advocacy._x000D_

_x000D_

In the coming years, a swift expansion in the cancer profiling market size is projected. It is expected to enlarge to$22.97 billion by 2029 with a compound annual growth rate (CAGR) of 11.2%. Factors such as the incorporation of artificial intelligence in diagnosis, worldwide research collaborations, increased use of liquid biopsy applications, official approval for precision medication, and escalating focus on early detection all contribute to this growth within the forecast period. The forecast period will also witness a surge in liquid biopsy usage, extensive genomic profiling, the increasing prevalence of immunoprofiling, cooperative data sharing networks, and the advent of single-cell sequencing._x000D_

_x000D_

#Download a free sample to assess the report’s scope and structure:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=9912&type=smp_x000D_

_x000D_

#What Are the Primary Drivers Supporting the Market Growth of the Cancer Profiling Market?#_x000D_

The escalating rate of cancer cases is predicted to fuel the expansion of the cancer profiling market. The term incidence of cancer relates to the tallies of new cancer instances within a specific demographic within a defined timeframe. The surge in cancer occurrences can be attributed to factors like urbanization, an aging population, lifestyle alterations, environmental impact, and genetic predispositions. Cancer profiling assists in pinpointing specific molecular or genetic shifts in a tumor, such as genetic mutations or other alterations in the tumor’s DNA, proving to be beneficial in the cycle of cancer treatment. For example, as per the American Cancer Society, a volunteer organization based in the U.S., the numbers projected for new cancer diagnoses and death in 2022 were approximately 1.9 million new cases and 609,360 deaths due to cancer in the United States. Therefore, the uptick in cancer occurrences is a significant driving force behind the growth of the cancer profiling market._x000D_

_x000D_

#Which Primary Segments of the Cancer Profiling Market Are Driving Growth and Industry Transformations?#_x000D_

The cancer profilingmarket covered in this report is segmented – _x000D_

_x000D_

1) By Technology: Immunoassays; PCR (Polymerized Chain Reaction); NGS (Next-Generation Sequencing); Microarrays; In-Situ Hybridization_x000D_

2) By Biomarker Type: Genomic Biomarkers; Protein Biomarkers_x000D_

3) By Cancer Type: Breast Cancer; Lung Cancer; Colorectal Cancer; Prostate Cancer; Melanoma Cancer; Other Cancers_x000D_

4) By Application: Research Applications; Clinical Applications; Screening; Diagnostics; Prognostics; Other Applications_x000D_

_x000D_

Subsegments:_x000D_

1) By Immunoassays: Enzyme-Linked Immunosorbent Assay (ELISA); Western Blotting; Luminex xMAP Technology; Radioimmunoassays _x000D_

2) By PCR (Polymerase Chain Reaction): Quantitative PCR (qPCR); Digital PCR (dPCR); Reverse Transcription PCR (RT-PCR) _x000D_

3) By NGS (Next-Generation Sequencing): Whole Genome Sequencing (WGS); Whole Exome Sequencing (WES); Targeted Sequencing; RNA Sequencing (RNA-Seq) _x000D_

4) By Microarrays: DNA Microarrays; RNA Microarrays; SNP Arrays _x000D_

5) By In-Situ Hybridization: Fluorescence In-Situ Hybridization (FISH); Chromogenic In-Situ Hybridization (CISH) _x000D_

_x000D_

#Request customized data on this market:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=9912&type=smp_x000D_

_x000D_

#Which Regions Are Key Players in the Growth of the #What Are the Primary Drivers Supporting the Market Growth of the Cancer Profiling Market?# Market?#_x000D_

North America was the largest region in the cancer profiling market in 2024. The regions covered in the cancer profiling market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa_x000D_

_x000D_

#What Are the Most Significant Market Trends in the Cancer Profiling Market?#_x000D_

Leading businesses in the cancer profiling industry are prioritizing innovative developments such as broad coverage. This type of testing analyses 517 genes relevant to cancer across about 30 different types of solid tumors. Broad coverage provides an extensive examination of a wide assortment of genetic mutations, molecular targets, or biomarkers. For example, in March 2022, the American biotech firm Illumina, Inc., introduced the TruSight Oncology Comprehensive (TSO) test, marking a significant milestone in cancer diagnosis. This new in-vitro diagnostic test in Europe profiles cancer mutations to direct patients towards targeted therapies. It encompasses 517 genes in approximately 30 solid tumor types, analyzing both DNA and RNA. With a turnaround of four to five days, it offers quicker results and meets the European quality standards with a CE mark, diminishing the requirements for multiple gene assays on various tissue samples._x000D_

_x000D_

#View the full report here:#_x000D_

https://www.thebusinessresearchcompany.com/report/cancer-profiling-global-market-report_x000D_

_x000D_

#What Parameters Are Used to Define the Cancer Profiling Market?#_x000D_

Cancer profiling refers to a diagnostic procedure that is conducted to analyze the genetic information of tumor cells in the body. It provides information about certain molecular or genetic changes in a tumor, such as gene mutations or other changes in tumor DNA._x000D_

_x000D_

#Purchase the full report and get a swift delivery:#_x000D_

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=9912_x000D_

_x000D_

#About The Business Research Company:#_x000D_

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_

_x000D_

#Get in touch with us:#_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas +1 310-496-7795_x000D_

Europe +44 7882 955267_x000D_

Asia & Others +44 7882 955267 & +91 8897263534_x000D_

Email us at info@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

September 13, 2025
Cancer ProfilingMarket Overview 2025–2034: CAGR Trends, Long-Term Growth Paths, and Business Implications

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Fast Is The Cancer Profiling Market Expected to Grow Between 2025 And 2029?

Over the past years, the market size for cancer profiling has witnessed quick expansion. The market value, which stood at $13.48 billion in 2024, is predicted to increase to $15 billion in 2025, registering a compound annual growth rate (CAGR) of 11.3%. The substantial growth in the past can be credited to factors such as escalating rates of cancer cases, growth in precision medicine methods, the clinical utilization of biomarkers, drug development and targeted therapies, increased awareness, and patient advocacy.

In the coming years, a swift expansion in the cancer profiling market size is projected. It is expected to enlarge to$22.97 billion by 2029 with a compound annual growth rate (CAGR) of 11.2%. Factors such as the incorporation of artificial intelligence in diagnosis, worldwide research collaborations, increased use of liquid biopsy applications, official approval for precision medication, and escalating focus on early detection all contribute to this growth within the forecast period. The forecast period will also witness a surge in liquid biopsy usage, extensive genomic profiling, the increasing prevalence of immunoprofiling, cooperative data sharing networks, and the advent of single-cell sequencing.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9912&type=smp

What Are the Primary Drivers Supporting the Market Growth of the Cancer Profiling Market?

The escalating rate of cancer cases is predicted to fuel the expansion of the cancer profiling market. The term incidence of cancer relates to the tallies of new cancer instances within a specific demographic within a defined timeframe. The surge in cancer occurrences can be attributed to factors like urbanization, an aging population, lifestyle alterations, environmental impact, and genetic predispositions. Cancer profiling assists in pinpointing specific molecular or genetic shifts in a tumor, such as genetic mutations or other alterations in the tumor’s DNA, proving to be beneficial in the cycle of cancer treatment. For example, as per the American Cancer Society, a volunteer organization based in the U.S., the numbers projected for new cancer diagnoses and death in 2022 were approximately 1.9 million new cases and 609,360 deaths due to cancer in the United States. Therefore, the uptick in cancer occurrences is a significant driving force behind the growth of the cancer profiling market.

Which Primary Segments of the Cancer Profiling Market Are Driving Growth and Industry Transformations?

The cancer profilingmarket covered in this report is segmented –

1) By Technology: Immunoassays; PCR (Polymerized Chain Reaction); NGS (Next-Generation Sequencing); Microarrays; In-Situ Hybridization

2) By Biomarker Type: Genomic Biomarkers; Protein Biomarkers

3) By Cancer Type: Breast Cancer; Lung Cancer; Colorectal Cancer; Prostate Cancer; Melanoma Cancer; Other Cancers

4) By Application: Research Applications; Clinical Applications; Screening; Diagnostics; Prognostics; Other Applications

Subsegments:

1) By Immunoassays: Enzyme-Linked Immunosorbent Assay (ELISA); Western Blotting; Luminex xMAP Technology; Radioimmunoassays

2) By PCR (Polymerase Chain Reaction): Quantitative PCR (qPCR); Digital PCR (dPCR); Reverse Transcription PCR (RT-PCR)

3) By NGS (Next-Generation Sequencing): Whole Genome Sequencing (WGS); Whole Exome Sequencing (WES); Targeted Sequencing; RNA Sequencing (RNA-Seq)

4) By Microarrays: DNA Microarrays; RNA Microarrays; SNP Arrays

5) By In-Situ Hybridization: Fluorescence In-Situ Hybridization (FISH); Chromogenic In-Situ Hybridization (CISH)

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=9912&type=smp

Which Regions Are Key Players in the Growth of the #What Are the Primary Drivers Supporting the Market Growth of the Cancer Profiling Market?# Market?

North America was the largest region in the cancer profiling market in 2024. The regions covered in the cancer profiling market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

What Are the Most Significant Market Trends in the Cancer Profiling Market?

Leading businesses in the cancer profiling industry are prioritizing innovative developments such as broad coverage. This type of testing analyses 517 genes relevant to cancer across about 30 different types of solid tumors. Broad coverage provides an extensive examination of a wide assortment of genetic mutations, molecular targets, or biomarkers. For example, in March 2022, the American biotech firm Illumina, Inc., introduced the TruSight Oncology Comprehensive (TSO) test, marking a significant milestone in cancer diagnosis. This new in-vitro diagnostic test in Europe profiles cancer mutations to direct patients towards targeted therapies. It encompasses 517 genes in approximately 30 solid tumor types, analyzing both DNA and RNA. With a turnaround of four to five days, it offers quicker results and meets the European quality standards with a CE mark, diminishing the requirements for multiple gene assays on various tissue samples.

View the full report here:

https://www.thebusinessresearchcompany.com/report/cancer-profiling-global-market-report

What Parameters Are Used to Define the Cancer Profiling Market?

Cancer profiling refers to a diagnostic procedure that is conducted to analyze the genetic information of tumor cells in the body. It provides information about certain molecular or genetic changes in a tumor, such as gene mutations or other changes in tumor DNA.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=9912

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

September 10, 2025
Cancer Profiling Market Projected at $23.08 Billion by 2029 | Strategic Insights and Forecast Data

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Cancer Profiling Market Size Changed, over the years?

In recent years, the market size for cancer profiling has seen significant growth. It is projected to expand from $13.48 billion in 2024 to $15.05 billion in 2025, representing a compound annual growth rate (CAGR) of 11.6%. Factors contributing to this growth in the past include an uptick in the rates of cancer diagnosis, an increase in the precision of medicine techniques, clinical usage of biomarkers, the development of drugs and targeted therapies as well as increased public awareness and advocacy for patients.

How Much Will the Cancer Profiling Market Be Worth in 2029?

The market size for cancer profiling is predicted to experience a swift expansion in the following years, reaching $23.08 billion in 2029, boasting a compound annual growth rate (CAGR) of 11.3%. The anticipated growth during the forecast period is linked to the inclusion of artificial intelligence, worldwide research partnerships, broadening the usage of liquid biopsy applications, regulatory backing for precision medicine, and a growing focus on early detection. The major market trends for the forecast period include the dominance of liquid biopsy, comprehensive genomic profiling, the rise of immunoprofiling, the growth of collaborative data sharing networks, and single-cell sequencing.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9912&type=smp

Which is the Largest Company in the Cancer Profiling Market?

Major companies operating in the cancer profiling market include Illumina Inc., Qiagen NV, NeoGenomics Inc., Sysmex Corporation, HTG Molecular Diagnostics Inc., Caris Life Sciences, NanoString Technologies Inc., Guardant Health Inc., Foundation Medicine Inc., Roche Diagnostics Corporation, F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Genscript Biotech Corporation, Tempus Labs Inc., Hologic Inc., Predictive Oncology Inc., Abbott Laboratories, Agilent Technologies Inc., PerkinElmer Inc., Siemens Healthineers, Genomic Health Inc., Natera Inc., ArcherDX Inc., Personal Genome Diagnostics Inc., Enzo Biochem Inc., Cancer Genetics Inc., OncoDNA SA, Ribomed Biotechnologies Inc., Biocartis Group NV, N-of-One Inc., Cynvenio Biosystems Inc., Inivata Ltd., Burning Rock Biotech Limited, PathAI Inc., GENEWIZ Inc., Genoptix Inc., Oncomine Dx Target Test, OmniSeq Comprehensive, Resolution Bioscience, OncoCyte Corporation

What Are the Main Market Drivers in the Cancer Profiling Industry?

The rise in cancer prevalence is forecasted to boost the expansion of the cancer profiling market. The term “cancer incidence” refers to the number of new cancer diagnoses within a certain population over a specific duration. This surge in cancer cases can be attributed to urbanization, an increasing elderly population, lifestyle changes, as well as environmental and genetic aspects. Cancer profiling helps detect specific changes in a tumor’s molecular makeup, including gene mutations or changes in the tumor’s DNA, which greatly aids in the treatment process in cancer care. For example, in 2022, the American Cancer Society, a voluntary organization based in the U.S., predicted around 1.9 million new cancer diagnoses and approximately 609,360 cancer-related fatalities in the United States. Hence, this rising prevalence of cancer is fuelling the growth of the cancer profiling market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=9912&type=smp

How Is the Cancer Profiling Market Segments Structured?

The cancer profiling market covered in this report is segmented –

1) By Technology: Immunoassays, PCR (Polymerized Chain Reaction), NGS (Next-Generation Sequencing), Microarrays, In-Situ Hybridization

2) By Biomarker Type: Genomic Biomarkers, Protein Biomarkers

3) By Cancer Type: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer, Other Cancers

4) By Application: Research Applications, Clinical Applications, Screening, Diagnostics, Prognostics, Other Applications

Subsegments:

1) By Immunoassays: Enzyme-Linked Immunosorbent Assay (ELISA), Western Blotting, Luminex xMAP Technology, Radioimmunoassays

2) By PCR (Polymerase Chain Reaction): Quantitative PCR (qPCR), Digital PCR (dPCR), Reverse Transcription PCR (RT-PCR)

3) By NGS (Next-Generation Sequencing): Whole Genome Sequencing (WGS), Whole Exome Sequencing (WES), Targeted Sequencing, RNA Sequencing (RNA-Seq)

4) By Microarrays: DNA Microarrays, RNA Microarrays, SNP Arrays

5) By In-Situ Hybridization: Fluorescence In-Situ Hybridization (FISH), Chromogenic In-Situ Hybridization (CISH)

What Strategic Trends Are Transforming the Cancer Profiling Market?

Prominent companies in the cancer profiling industry are emphasizing innovation such as extensive coverage in their developments. This testing method examines 517 genes pertinent to cancer across almost 30 different types of solid tumors. Comprehensive or extensive coverage involves an all-inclusive examination of a variety of genetic mutations, biomarkers, or molecular targets. For instance, Illumina, Inc., a biotech company based in the US, debuted the TruSight Oncology Comprehensive (TSO) test in March 2022, marking a considerable progression in cancer diagnosis. This new diagnostic test for in vitro use in Europe identifies cancer mutations to guide patients towards specific therapies. It scans 517 genes across close to 30 types of solid tumors, analyzing both DNA and RNA. With a turnaround of four to five days, the test delivers results faster and complies with European quality standards marked by CE, meeting the demand for multiple gene tests on different tissue samples.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/cancer-profiling-global-market-report

Which Global Regions Offer the Highest Growth in the Cancer Profiling Market?

North America was the largest region in the cancer profiling market in 2024. The regions covered in the cancer profiling market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=9912

This Report Delivers Insight On:

1. How big is the cancer profiling market, and how is it changing globally?

2. Who are the major companies in the cancer profiling market, and how are they performing?

3. What are the key opportunities and risks in the cancer profiling market right now?

4. Which products or customer segments are growing the most in the cancer profiling market?

5. What factors are helping or slowing down the growth of the cancer profiling market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

July 17, 2025